-- Data supporting selection of ROR1 for CB-020 and armoring strategies for Caribou’s CAR-NK cell platform to be presented at AACR-JCA Conference today -- -- Caribou is using its chRDNA next-gen ...

Latent cardiovascular toxicity issues continue to plague late-stage drug discovery efforts, as well as commercially launched pharmaceutical success. Many current in vitro models lack, or incompletely ...

An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models. The consensus rating for Century Therapeutics is "Buy", ...

Caldwell, Idaho – 26 January, 2016 –Regarded as the leader in steel target innovation and manufacturing for over 20 years, MGM Targets saw a need for development of a versatile, durable and economical ...

Century Therapeutics (NASDAQ:IPSC – Free Report) had its target price cut by HC Wainwright from $5.00 to $2.00 in a research report report published on Thursday morning,Benzinga reports. They ...

BERKELEY, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced target selection ...